aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating

Biotech company aTyr Pharma’s (NASDAQ: ATYR ) first of two pivotal events of the year is coming up. The first one is an interim readout and will be the least interesting one in my perspective, as it relates to aI am a long-term investor focused on growth markets, AI and biotech opportunities in my more volatile portfolio. I try to look for undervalued and under-the-radar stocks with serious potential and good scientific or other background. My ambition here is to cover stocks with considerable growth potent ...